Optical Coherence Tomography Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 2.59 Bn

Forecast Year, 2035

USD 11.01 Bn

CAGR, 2026 - 2035

15.57%

Report Coverage

Global

What is the Optical Coherence Tomography Market Size?

The global optical coherence tomography market size is calculated at USD 2.59 billion in 2025 and is predicted to increase from USD 3 billion in 2026 to approximately USD 11.01 billion by 2035, expanding at a CAGR of 15.57% from 2026 to 2035. The demand for OCT devices has increased due to the rising prevalence of eye disorders. The growing need for early disease diagnosis and demand for non-invasive devices are driving the market.

Optical Coherence Tomography Market Key Takeaways

• North America dominated the global market with the largest market share of 35% in 2025.
• Asia Pacific is expected to host the fastest-growing market during the forecast period.
• By type, the handheld segment contributed the largest market share of 47% in 2025.
• By type, the Doppler OCT segment is expected to grow fastest CAGR of 17.34% during the forecast period.
• By technology, the frequency domain optical coherence tomography (FD-OCT) segment generated the biggest market share of 38% in 2025.
• By technology, the spatial encoded frequency domain OCT segment is projected to grow at the fastest CAGR of 16.43% during the forecast period.
• By application, the ophthalmology segment contributed the highest market share of 56% in 2025.
• By application, the dermatology segment is estimated to register the remarkable CAGR of 21.44% during the forecast period.

What is the Significance of Optical Coherence Tomography?

The optical coherence tomography market reflects the non-invasive imaging test, which uses low-coherence interferometry to get high-resolution imaging. The growing prevalence of chronic diseases related to the eye, skin, and other tissues is driving the utilization of optical coherence tomography devices. The ability of OCT devices, including non-invasive images, high-resolution, and real-time imaging, makes them ideal for healthcare utility. Increased prevalence of disease in the aging population is the major trend for the adoption of technology.

Ophthalmology is the primary adopter of OCT technology due to the increased prevalence of eye-related diseases. The technology is widely used in dermatology , cardiology, and oncology . Increased risk of skin cancer is driving innovative approaches in optical coherence tomography. Pharmaceutical companies and the government are contributing huge investments in research and developments to advance the speed, sensitivity, and resolution capabilities of OCT devices, making a spectacular impact on the optical coherence tomography market growth. Additionally, regulatory support for novel, innovative technologies plays a pivotal role in the accessibility and adaptability of OCT technologies in healthcare settings.

• In October 2024, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Gentuity, LLC's Gentuity HF-OCT Imaging System, which features the Vis-Rx Micro-Imaging Catheter, for before and after percutaneous coronary intervention (PCI) use. The system is the only intravascular imaging platform specifically indicated for the assessment of the coronary vessel pre- and post-intervention.

Why is AI playing a vital role in optical coherence tomography?

The optical coherence tomography offers non-invasive, accurate, high-resolution, and real-time imaging. Artificial Intelligence integration with this technology is scaling up in its capabilities and sensitivity. AI algorithms provide improved image analysis and disease detection. The increased demand for OCT to provide early disease detection is a prior and high-potential area for AI implementation. AI has made it easier for disease detection and classification.

AI can standardize OCT technology by minimizing the variation between different clinicians, improving disease management and real-time monitoring. AI has proven extreme throughput in dealing with complex retinal structures and diseases like age-related macular degeneration (AMD) and glaucoma by making OCT scans more informative and efficient to advance the understanding of healthcare providers. With the implementation of AI, optical coherence tomography is expected to develop high-speed, accuracy, and other cutting-edge capabilities.

Optical Coherence Tomography Market Growth Factors

• Demand for early disease diagnosis: The demand for early disease diagnosis has grown due to increased awareness and the importance of early diagnosis and treatments, significantly impacting the adoption of OCT devices.
• Increased eye disorder prevalence: The prevalence of eye-related disorders such as diabetic retinopathy, glaucoma, and age-related macular degeneration is rising, driving demand for OCT devices.
• Demand for non-invasive technology: The increased prevalence of chronic disease, especially age-related eye disorders, is driving demand for non-invasive and no-contact technologies.
• Technology advancement: The advancement in technology, such as spectral-domain OCT and swept-source OCT, is enabling access to imaging speed and high resolution, leading to a high adoption rate.
• Healthcare expenditure: Expanding advanced healthcare expenditure, driving adoption of edge technologies, including OCT technologies, for high-speed, high-resolution, and non-invasive diagnostics and treatments. Growing collaborations between the healthcare industry and manufacturing companies are improving segment advancements and affordability.

Optical Coherence Tomography Market Outlook

[[market_outlook]]

Market Scope

Market Dynamics

Drivers

Increased eye-related disorder prevalence

The prevalence of eye-related disorders such as diabetic retinopathy , age-related macular degeneration, and glaucoma has increased around the globe. The aging population and the rising incidence of age-related eye diseases like macular degeneration. The risk of causes of vision impairment and blindness is driving demand for non-invasive early detection diagnostics. The increased prevalence of eye-related diseases has led to a growth in demand for faster scanning speeds and improved image quality. The optical coherence tomography market technology provides a highly accurate and detailed way to diagnose and monitor eye-related disease conditions. The need for early detection and accurate and fast treatment management is driving the adoption of OCT technologies and devices.

Restraint

High cost associated with equipment

The OCT equipment is expensive, which makes a significant hindrance in their adoption rate. OCT equipment requires high-resolution imaging capabilities, which can be expensive. Costs associated with manufacturing and maintenance of OCT equipment can be expensive. OCT equipment uses edge technologies like high-speed scanning and low-coherence interferometry, which cause high-cost developments and manufacturing. The utilization of an imaging method that uses reflected light to create pictures further makes OTC equipment expensive. The high cost of regulating and upgrading OCT equipment is the biggest challenge for healthcare providers.

Opportunity

Demand for early diagnosis of diseases

The increased prevalence of chronic diseases is driving the need for early diagnostics. The adoption of ophthalmology for eye disease monitoring and diagnosis is rising. Adoption of advanced technologies in OCT devices, such as Higher-resolution images and Faster scanning speeds, is improving efficiency and patient outcomes. OCT is widely accepted in cardiology, making it essential for adoption rates. The advancements in portable and handheld OCT devices are gaining popularity. High-resolution imaging, real-time imaging, and non-invasive imaging modalities of OCT are enhancing early detection and diagnostics management for disease.

Segment Insights

[[segment_insights]]

Regional insights

[[regional_insights]]

Optical Coherence Tomography Market Companies

[[market_company]]

Other Major Key Players

• Thorlabs, Inc
• Abbott

Leader's Announcements

• In October 2024, Dr. Alasdair Price, CEO of Siloton, announced that Siloton brought a uniquely qualified team together to develop technology at an unprecedented pace. The new funding support will help Siloton to scale up its commercialization by shifting gear from R&D to product development, he added.
• In February 2025, Optos Chief Executive Officer Robert Kennedy announced that the MonacoPro represents the company's commitment to continuous innovation in ophthalmic imaging. The company is empowering clinicians with tools to improve efficiency and diagnostic confidence while maintaining industry-leading ultra-widefield imaging capabilities by advancing automation and data analysis.

Segments Covered in the Report

[[segment_covered]]